Overview

Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY94-9392 in patients with cancer or inflammation.
Phase:
Phase 1
Details
Lead Sponsor:
Life Molecular Imaging SA
Piramal Imaging SA